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OBJECTIVE — Tocomparetheabilityofgenericcomorbidityandriskadjustmentmeasures,
a diabetes-speciﬁc measure, and a self-reported functional status measure to explain variation in
health care expenditures for individuals with diabetes.
RESEARCHDESIGNANDMETHODS — Thisstudyincludedaretrospectivecohortof
3,092 diabetic veterans participating in a multisite trial. Two comorbidity measures, four risk
adjusters, a functional status measure, a diabetes complication count, and baseline expenditures
were constructed from administrative and survey data. Outpatient, inpatient, and total expen-
diture models were estimated using ordinary least squares regression. Adjusted R
2 statistics and
predictive ratios were compared across measures to assess overall explanatory power and ex-
planatory power of low- and high-cost subgroups.
RESULTS — Administrative data–based risk adjusters performed better than the comorbid-
ity, functional status, and diabetes-speciﬁc measures in all expenditure models. The diagnostic
cost groups (DCGs) measure had the greatest predictive power overall and for the low- and
high-cost subgroups, while the diabetes-speciﬁc measure had the lowest predictive power. A
model with DCGs and the diabetes-speciﬁc measure modestly improved predictive power.
CONCLUSIONS — Existing generic measures can be useful for diabetes-speciﬁc research
and policy applications, but more predictive diabetes-speciﬁc measures are needed.
Diabetes Care 32:75–80, 2009
C
omorbidity and risk adjustment
measures are routinely used for out-
comes assessment (1,2), outlier
identiﬁcation (3,4), performance evalua-
tion and proﬁling (5–8), program eval-
uation, and payment setting (9).
Comorbidity adjustment gained promi-
nence when the diagnosis-based Charl-
son Comorbidity Index (CCI) was
developed in 1987 to predict inpatient
mortality (10). Subsequent comorbidity
and self-reported functional status mea-
sures have improved upon the CCI for
prediction of clinical and economic out-
comes in general samples taken from
largerpatientpopulationsthatarenotdis-
ease speciﬁc and from disease-speciﬁc
samples (1,11–13).
Risk adjustment measures incorpo-
ratingdemographic,comorbidity,disease
severity, or functional status have been
used to improve expenditure prediction
for payment setting and to reduce health
plan and provider incentives to enroll the
healthiest patients (14). It is not straight-
forwardtochooseamongseveralexisting,
validated generic comorbidity and risk
adjustment measures in expenditure
analyses. When choosing a measure, re-
searchers must consider the purpose of
the measure in the planned analysis, the
outcome and population on which the
measure’s original validation was con-
ducted, the measure’s predictive power,
and availability of data to construct the
measure.
If the expenditure analysis is con-
ducted on a general sample, then prior
comparisons of generic measures can in-
form measure choice (13,15). If the ex-
penditure analysis is conducted on a
disease-speciﬁc sample, existing disease-
speciﬁc measures must also be consid-
ered. Disease-speciﬁc measures may
capture variation in disease severity more
effectively, include data sources not cap-
tured in comorbidity or risk adjustment
measures (e.g., lab data), and avoid ceil-
ing or ﬂoor effects of generic measures
(16).
The purpose of this study is to com-
parethepredictivepowerofsevengeneric
measures, one diabetes-speciﬁc measure,
and baseline health care expenditures
among diabetic individuals (15). The
seven generic measures include two co-
morbidity measures (the CCI and the Se-
attle Index of Comorbidity [SIC]), four
risk adjusters (adjusted clinical groups
[ACGs], diagnostic cost groups [DCGs],
the Chronic Illness and Disability Pay-
ment System [CDPS], and RxRisk), and a
self-reported functional status measure
(combinedphysicalcomponentsummary
[PCS] and mental component summary
[MCS] scores from the short-form [SF]-
36). We chose a diabetic cohort because
diabetes is a highly prevalent, costly
chronic condition and there are several
diabetes-speciﬁc measures (17–19). For
this analysis, we chose a diabetes compli-
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quire data not captured in this study.
We also examined the accuracy of the
expenditure predictions for low- and
high-costsubgroupstoillustratepotential
tradeoffs between overall and subgroup
predictivepower.Thisistheﬁrstreportto
examine the potential tradeoffs in generic
and disease-speciﬁc measures for risk ad-
justment; the criteria for evaluating mea-
sures and the relative ranking of the
measures’ predictive power can inform
expenditure analyses in other disease-
speciﬁc samples.
RESEARCH DESIGN AND
METHODS— The sample was drawn
from patients in primary care clinics from
seven Veterans Health Administration
medical centers that participated in the
Ambulatory Care Quality Improvement
Project(ACQUIP)trialbetween1997and
2000 (19). Veterans were eligible to par-
ticipateinthetrialiftheyhadtovisittheir
assigned primary care provider in one of
seven participating sites in the year before
thebeginningofthestudy.Atotalof21,260
(62%) of 34,103 eligible veterans from all
seven participating sites responded to a
health-screening questionnaire and were
sent a baseline SF-36 (20) (Fig. 1). Of
21,260veterans,4,790hadbeentoldbya
physicianthattheyhaddiabetes(ofeither
type) and provided complete SF-36 data.
Diabetes-speciﬁc surveys were available
from 2,287 of 4,790 veterans. We im-
puted SF-36 scores on another 805 veter-
ans with diabetes who had incomplete or
missing baseline SF-36 data, based on the
average values from two SF-36 surveys
completed by the patient before the base-
line survey or a carry-forward of the
SF-36 values from the closest survey be-
fore baseline. Imputed values did not sig-
niﬁcantly alter the mean PCS and MCS
scores from the SF-36 in our sample. The
ﬁnalsampleincluded3,092veteranswith
complete data.
Construction of health care
expenditures
The dependent variables were inpatient,
outpatient, and total expenditures con-
structed for the year following the base-
line year to enable prospective risk
adjustment. We calculated an index date
for each respondent indicating the end of
the baseline year and the beginning of the
follow-up year. Patient-level expenditure
datawerecalculatedfromVeteransAffairs
(VA)administrativedataintheoutpatient
care ﬁles and inpatient treatment ﬁles.
The method for deriving expendi-
tures is described elsewhere (15). Brieﬂy,
outpatientexpendituresweretheproduct
of visits and unit costs for outpatient clin-
ics,includingoutpatientlabtestsandpro-
cedures. Inpatient expenditures for
nonmedical and nonsurgical hospitaliza-
tions (e.g., psychiatry) were the product
of length of stay and a per diem rate. In-
patient expenditures for medical or surgi-
cal hospitalizations were calculated using
an expenditure function based on age,
sex, discharge disposition, bedsection(s),
length of stay, and medicare DRG
weights. Outpatient VA pharmacy and
non-VAexpenditureswereexcluded.The
dependent variables were annualized by
mortality weights for those who died in
the prediction year, based on the fraction
of prediction year in which the individual
was alive.
Comorbidity, risk adjustment,
functional status, and diabetes
complication measures
Seven generic measures, one diabetes-
speciﬁc measure, and baseline expendi-
tures were used to predict inpatient,
outpatient, and total expenditures. The
two generic comorbidity measures were
the CCI and the SIC. The CCI was origi-
nally developed as a means of classifying
the number and seriousness of comorbid
conditions to predict 1-year mortality
based on diagnoses from medical charts
(10). We used the Deyo-modiﬁed Charl-
son using inpatient diagnoses from VA
administrativedata(21).TheSICisbased
on self-reported chronic condition indi-
cators, age, and smoking status from the
ACQUIP initial screening questionnaire.
The SIC was developed to predict 2-year
mortalityandhospitaladmission(22)and
predicted expenditures poorly in the
overall ACQUIP sample (15).
The four risk adjustment measures
wereDCGs,ACGs,theCDPS,andRxRisk
scores constructed from VA administra-
tivedata.TheDCGs,ACGs,andCDPSare
based on both inpatient and outpatient
diagnoses, while the RxRisk is based on
medication reﬁll data. DCGs were origi-
nally developed to predict Medicare ex-
penditures, are the most widely
implemented risk adjuster in payment
settings (9), and have predicted total VA
expenditures better than other risk ad-
justers (15). ACGs (14) are another
widely used risk adjustment measure for
expenditure analyses and have been ap-
plied in VA expenditures analyses (6,15).
TheCDPSmeasurewasdevelopedtopre-
dict Medicaid expenditures and was in-
cluded because the source code is
publicly available and VA and Medicaid
patients have similar chronicity (23). The
Figure 1—Analytic sample obtained from ACQUIP trial participants with diabetes. *Enough
responses to allow scoring of PCS and MCS.
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care visits, hospitalizations, and expendi-
tures in VA and managed-care popula-
tions (3,6,13,15); this study used the
RxRisk tailored to the VA population
(RxRisk-V) (24). Standardized risk scores
for ACG, DCG, the CDPS, and the RxRisk
riskmeasureswerecalculatedbydividing
each patient’s predicted score by the av-
erage total expenditure for a reference
population (veterans in the ACQUIP
study).
The functional status measures (PCS
and MCS scores [20]) were included in
this analysis because of their use in previ-
ous risk adjustment studies. The PCS and
MCS are standardized to a general popu-
lation with a mean of 50  10; higher
scores indicate better health. Baseline to-
tal expenditures were also modeled be-
cause they are highly correlated with
expenditures in the next year and were
usedtocontrolforunobservedhealthsta-
tus differences in expenditure analyses
until risk adjustment measures became
widely available. The diabetes-speciﬁc
measure was a count of diabetes compli-
cations, a diagnosis-based measure of ret-
inopathy, nephropathy, neuropathy,
cerebrovascular, cardiovascular, periph-
eral vascular disease, and metabolic com-
plications originally developed to explain
mortality and the number of hospitaliza-
tions in a 4-year period (18).
Analysis
We regressed expenditures in prediction
year t against each risk adjuster and age-
sex categories at year t-1 using weighted
ordinary least squares. The 14 age-sex
categories constructed and used in each
modelincludedwomenaged18–44,45–
64, and 65 years in order to ensure suf-
ﬁcient cell sizes and men aged 18–44,
45–49, 50–54, 55–59, 60–64, 65–69,
70–74, 75–79, 80–84, and 85 years.
AdjustedR
2valueswereusedtocom-
parethepredictiveaccuracyinthecohort.
Predictive accuracy for patients in the
lowest and highest expenditure quintiles
was assessed by predictive ratios, calcu-
lated by dividing the sum of within-
quintile predicted expenditures by the
sum of within-quintile actual expendi-
tures. Risk adjusters with less overpredic-
tion in the highest quintiles and less
underprediction in the lowest quintiles
(indicated by predictive ratios closer to
1.0) are preferred.
RESULTS— Nearly all veterans with
diabetes(98%)weremale;theaverageage
was 64 years (Table 1). Baseline total ex-
penditures averaged $5,737, including
outpatientexpendituresof$2,917andin-
patient expenditures of $2,820. Mean to-
tal expenditures in the prediction year
were considerably higher ($7,410), due
to a 50% increase in inpatient expendi-
tures ($4,205). The mean PCS and MCS
values were 31.2 and 44.8, respectively,
which are below population norms of 50.
The SIC and CCI measures had mean val-
ues of 8.0 (range 2–20) and 0.5 (0–14),
respectively. The ACG, DCG, the CDPS
and the RxRisk standardized scores were
all 1.0, indicating that these veterans
with diabetes were higher risk than the
reference population (ACQUIP partici-
pants). The mean number of diabetes
complications was 0.7 (0–5).
All measures, except age/sex alone,
had the greatest predictive power for out-
patient expenditures and the least power
for inpatient expenditures (Table 2). In
the total expenditure model, the diabetes
complications count had the lowest ad-
justed R
2 (0.10%), followed by age/sex
(0.14%), PCS, and MCS from the SF-36
(0.64%) and the SIC (0.65%). Prior-year
expenditures and the CDPS were slightly
better (2.8 and 3.02%), followed by the
RxRisk-V (3.23%), the CCI (3.26%), and
the ACG (3.56%). The DCG measure ex-
plained the most variation in total expen-
ditures(5.6%),andamodelthatincluded
DCGanddiabetescomplicationmeasures
explained modestly more expenditure
variation (adjusted R
2  5.8%).
Similar to the results of the total ex-
penditure analysis, the diabetes compli-
cation (0.10%), age/sex (0.18%), and
PCS-MCS (0.23%) models explained the
least variation in inpatient expenditures.
The SIC (0.5%), prior-year expenditures
Table 1—Descriptive statistics of a sample of veterans regularly using primary care
Mean  SD Minimum Maximum
Dependent variables
Prediction year total expenditure ($) 7,410  22,071 0 589,019
Prediction year outpatient expenditure ($) 3,205  3,869 0 68,116
Prediction year inpatient expenditure ($) 4,205  21,138 0 589,019
Explanatory variables
Age (years) 64  10 27 93
Male (%) 98 — —
PCS 31.2  10.8 6.0 65.4
MCS 44.8  12.9 10.6 73.3
SIC 8.0  2.8 2 20
CCI 0.5  1.3 0 14
ACG 1.3  0.8 0.1 3.3
DCG 1.8  1.3 0 10.6
CDPS 2.5  1.6 0.1 13.9
RxRisk-V 1.6  0.9 0 9.3
Diabetes complications count 0.7  0.7 0 5
Base year total expenditure ($) 5,737  10,752 0 180,490
Base year outpatient expenditure ($) 2,917  3,272 0 63,590
Base year inpatient expenditure ($) 2,820  9,399 0 176,306
N  3,092.
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RxRisk-V (1.3%) models performed
slightly better. Unlike the total expendi-
ture analyses, the ACG model per-
formed less well than the CCI model
(1.3 vs. 1.7%). The best-performing
models were the DCG model (2.4%)
and the combined DCG and diabetes
complication count model (2.6%).
None of these models performed well in
absolute terms. The relative rankings of
measures in outpatient expenditure
prediction were generally similar to in-
patientandtotalexpenditures,withone
exception. Prior-year expenditures ex-
plained a signiﬁcantly higher percent-
age (35%) of outpatient expenditures
than other models.
Predictive ratios were compared across
measurestoillustratethedegreeofoverpre-
diction or underprediction by expenditure
quintile (Table 3). All models signiﬁcantly
overpredicted the lowest quintile and
signiﬁcantly underpredicted the highest
quintile. ACGs and DCGs had less overpre-
diction in the lowest quintiles and less un-
derprediction in the highest quintile. The
model including DCG and the diabetes
complications count further reduced over-
predictioninthelowestquintileandunder-
prediction in the highest expenditure
quintile, suggesting that this model per-
formedbestinthelow-costgroup,thehigh-
cost group, and in the overall sample.
CONCLUSIONS — Comorbidity,
risk adjustment, and functional status
measures vary widely in their power to
explain expenditure variation and to dis-
Table 2—Alternative risk adjustment measures in prospective expenditure models
Risk adjustment model
Total expenditures Inpatient expenditures Outpatient expenditures
Adjusted R
2 Rank Adjusted R
2 Rank Adjusted R
2 Rank
Age and sex alone (%) 0.14 10 0.18 10 0.22 10
Prior-year expenditure 2.80 7 0.58 7 35.10 1
Functional status measure
PCS  MCS (from SF-36) 0.64 9 0.23 9 2.59 8
Comorbidity measures
CCI (%) 3.26 4 1.71 3 7.75 7
SIC 0.65 8 0.49 8 0.79 9
Risk adjustment measures
ACG 3.56 3 1.33 4 14.80 5
DCG-HCC 5.58 2 2.36 2 19.63 3
CDPS 3.02 6 0.90 6 16.25 4
RxRisk-V 3.23 5 1.33 4 11.79 6
Diabetes-speciﬁc measure
Diabetes complications count 0.10 11 0.10 11 0.22 10
DCG-HCC  diabetes complications count 5.80 1 2.55 1 20.04 2
N  3,092. All self-report and diagnosis-based measures include age and sex. The PCS and MCS were included as distinct explanatory variables in the PCS  MCS
model above. Highest R
2 values are shown in bold face.
Table 3—Assessment of under- and overprediction by total expenditure quintile
Lowest
expenditure
quintile
Second lowest
expenditure quintile
Middle
expenditure
quintile
Second highest
expenditure quintile
Highest
expenditure
quintile
n 612 612 612 612 611
Age and sex alone 17.38 4.58 2.55 1.35 0.24
Prior expenditure 14.96 3.97 2.41 1.48 0.30
Functional status measure
PCS  MCS (from SF-36) 16.57 4.26 2.51 1.42 0.26
Comorbidity measures
CCI 15.41 4.00 2.45 1.39 0.32
SIC 16.88 4.39 2.57 1.36 0.26
Risk adjustment measures
ACG 11.81 3.59 2.51 1.61 0.33
DCG-HCC 11.71 3.40 2.41 1.56 0.37
CDPS 13.40 3.91 2.52 1.50 0.32
RxRisk-V 13.33 3.79 2.58 1.52 0.31
Diabetes-speciﬁc measure
Diabetes complicatons count 16.61 4.46 2.53 1.34 0.25
DCG-HCC  diabetes complication count 10.96 3.33 2.40 1.56 0.38
Predictiveratiosforeachexpenditurequintileshownherearecalculatedbydividingthesumofwithin-quintilepredictedexpendituresbythesumofwithin-quintile
actual expenditures, based on an ordinary least squares regression.
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However, the amount of variation in total
expenditures explained by any measure
never exceeded 6% and for most was
4%. The DCG measure explained the
most variation in total expenditures and
performed modestly better when com-
bined with the diabetes complication
count,possiblybecausetheDCGmeasure
accounts for severity to a limited but
greater degree than other risk adjustment
and comorbidity measures.
Thediabetescomplicationscountdid
not explain signiﬁcant variation in inpa-
tient,outpatient,ortotalexpendituresbe-
cause the potential range in this measure
wassmall,theobservedrangewaslimited
due to a fairly homogeneous sample, and
it did not reﬂect broader comorbidity dif-
ferences that generic measures take into
account.Overallpredictivepowerandac-
curate prediction of low- and high-cost
groups depend more on comprehensive
adjustment of comorbidities than on dis-
ease severity, even in a disease-speciﬁc
sample.Thegenericcomorbidityandrisk
adjustmentmeasuresexaminedherewere
originally designed to reduce confound-
ing by measuring comorbidity broadly in
general populations and are broadly ap-
plicable. A diabetes-speciﬁc measure that
captureddiabetesseveritymorefullywith
laboratory results and medication data
may perform better in expenditure pre-
diction than the complications count, but
wedidnothavethedatanecessarytocon-
struct such a measure.
This study has several limitations.
First, veterans with diabetes were identi-
ﬁed by self-report not by validated diag-
noses- or medication-based algorithms,
so it is possible that there are some false-
positives in our study. This is likely to be
minimal since self-report of diabetes is
consideredthegoldstandardwithasta-
tistic of 0.84 when compared with a clin-
ical diagnosis of diabetes from chart
review in the ACQIP trial. Second, the
relative ranking of measures may be sen-
sitive to regression method and speciﬁca-
tion in studies with small samples such as
ours (see online appendix I for predictive
ratios under a generalized linear model
with log costs [available at http://dx.doi.
org/10.2337/dc08-1099]). Third, non-
VAexpendituresandVAoutpatientphar-
macyexpenditureswerenotavailableand
may have underestimated our power.
These exclusions do not invalidate our
ﬁndings because the goal of the report
was to compare several measures on a
metric that is consistent across measures.
Fourth, the study results may not gener-
alize to patients with type 1 diabetes be-
cause of the lack of these patients in our
sample. Fifth, we were unable to cross-
validateourresultsbycreatingtestingand
validation samples that would have im-
proved the robustness and reliability of
the results because our sample size was
limited. Sixth, several of the comorbidity
and risk adjustment measures examined
here have been updated, so their predic-
tive power may have improved and rela-
tive ranking might change. We used ACG
version 4.2 software and DCG-HCC ver-
sion6.0softwareinthisanalysis,butACG
version 8.1 software is now available and
includes new DCG risk adjusters for the
CentersforMedicareandMedicaidServices
and other purposes. Finally, there may be
variation in diagnosis and medication cod-
ing practices within and across medical
centers, so diagnosis- and pharmacy-based
measures may have measurement error.
To guide analysts interested in using
existing, validated measures to adjust for
confounding due to comorbidity and
other differences, future research should
compare well-established generic risk ad-
justers and diabetes-speciﬁc measures in
mortality and other health outcomes.
Such comparisons will provide a better
understanding of the tradeoffs between
more complete capture of comorbidities
or more complete capture of disease se-
verity because no existing generic mea-
sure captures breadth (via comorbidities)
and depth (via severity) to the same degree.
Genericmeasurescapturecomorbidi-
ties imperfectly but reﬂect the severity of
the primary condition and predict differ-
ent outcomes with differing degrees of
power (25). For example, the CCI was
developed to predict mortality and does
sobetterthanmostmeasures,butitisless
predictive of expenditures than risk ad-
justment measures in this sample of vet-
erans with diabetes and in a general
veteran sample (15). The ranking of mea-
sures by predictive power in this sample
of veterans with diabetes is almost identi-
cal to the ranking for a general veteran
sample(15).ACGsandDCGsweredevel-
oped to predict expenditures, and DCGs
are generally the most predictive risk ad-
juster, but these measures do not predict
mortalityaswellascomorbiditymeasures
in a general veteran sample (13). On the
other hand, disease-speciﬁc measures
maycapturediseaseseveritywellbutmay
not capture comorbidities that are
strongly correlated with economic out-
comes. Expenditure prediction in dis-
ease-speciﬁc samples may be improved
by using generic and disease-speciﬁc
measures together in regression adjust-
ment if it is practical and consistent with
the measure’s original objective.
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